Anebulo Pharmaceuticals, Inc. · OTC:ANEB
Anebulo Pharmaceuticals — Technical Presentation (July 2022)
14 slides from Anebulo Pharmaceuticals's technical presentation, Jul 5, 2022
Slide 1: Top Line Part A Phase 2 Data for ANEB-001 in ACI
ANEBULO PHARMACEUTICALS Top Line Part A Phase 2 Data for ANEB-001 in ACI Tuesday July 5%, 2022
Slide 2: Forward Looking Statements
Forward Looking Statements Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21 of the Securities Exchange Act of 1934, as amended. These forward-looking statemen
Slide 3: ANEBULO: Addressing Acute Cannabinoid Toxicity
ANEBULO: Addressing Acute Cannabinoid Toxicity ¢ US based clinical stage biotech focused on ACI and substance abuse disorders * Focused on developing the first FDA approved therapy for ACI * ANEB-001 benefits from: v Positive Phase 2 Proof-of-Concept Data Anebulo’s issued patent and ongoing IP strat
Slide 4: Cannabis Associated Emergency Department Visits Increase
Cannabis Associated Emergency Department Visits Increase Annual cannabis associated ED visits in the U.S., 2006-2018 US Emergency Department Outside of NEDS (estimated) 1,741,747 admissions for cannabi 4,600,000 7 Bagi captured in NEDS intoxication increase at 15' 1,400,000 after “legalization” (201
Slide 5: Clinical Trial Design — Part A Challenge Study
ANEB-001: Clinical Trial Design — Part A Challenge Study Primary Objective: To investigate the ability of ANEB-001 to inhibit the psychotropic effects of A9-Tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis. Randomized, double-blind, placebo-controlled study Single Oral Dose,
Slide 6: Produced Sustained Reduction of Feeling High
ANEB-001: Produced Sustained Reduction of Feeling High VAS Feeling High logimm) ® ANEBULO 054 Time Course of VAS Feeling Hig! © THC/Placebo THC/50 mg ANEB-001 THC/100 mg ANEB-001 0.0 Time (hours) Administration of oral THC alone produced a substantial increase in the VAS feeling high score Coadminis
Slide 7: Reduced the Proportion of Subjects Feeling High
ANEB-001: Reduced the Proportion of Subjects Feeling High + 75% of subjects dosed with THC alone reported feeling high Only 10% of subjects given THC with 50 mg ANEB-001 and 30% of subjects given 60 THC with 100 mg ANEB-001 reported feeling high Coadministration of THC with ANEB-001 led to a highly
Slide 8: Produced Sustained Improvement in Alertness
ANEB-001: Produced Sustained Improvement in Alertness Time Course of VAS Alertness VAS alertness (mm) @ ANEBULO s+ 35 THO/Placebo THC/50 mg ANEB-001 THC/100 mg ANEB-001 Time (hours) Administration of oral THC alone produced a substantial reduction in alertness ANEB-001 significantly inhibited the re
Slide 9: Effect on THC-Induced Body Sway
ANEB-001: Effect on THC-Induced Body Sway Administration of oral THC alone @ = THC/Placebo produced an increase in body sway, 4004 4 THC/100 mg ANEB-001 although inter-subject variability was THC/S0 mg ANEB-001 high + Coadministration of THC with ANEB-001 showed a trend towards reduced body sway The
Slide 10: Effect on Heart Rate
ANEB-001: Effect on Heart Rate Time Course of Heart Rate 704 @ ‘qHewImeEs repeatedly during the study ™ = THC/50 mg ANEB-001 Administration of THC alone had A THC/100 mg ANEB-001 only a minor effect on heart rate Coadministration of THC with ANEB-001 showed a trend towards normalization of heart rat
Slide 11: Topline Data for Part A of Phase 2 POC Study
ANEB-001: Topline Data for Part A of Phase 2 POC Study Primary Outcomes: * VAS Feeling High: Highly significant and sustained improvement ANEB-001 (p < 0.0001) at both dose levels Proportion of Subjects Reporting Feeling High on VAS: 75% for THC/placebo versus 10% on 50 mg ANEB-001 and 30% on 100 mg
Slide 12: Topline Data for Part A of Phase 2 POC Study
ANEB-001: Topline Data for Part A of Phase 2 POC Study Secondary Outcomes: » VAS external perception: Significant improvement at both dose levels (p < 0.01) » VAS nausea: No significant difference overall between treatment groups * Other secondary VAS scores: No significant differences between treat
Slide 13: Next Steps
ANEB-001: Next Steps Development Awaiting final safety and PK data from Part A Completion of Part A data analysis and PK/PD correlations Initiation of Part B of the Phase 2 study to explore a lower ANEB-001 dose and a higher THC challenge dose Discussions ongoing with FDA's Model-Informed Drug Devel
Slide 14: Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. Scott Anderson Head of Investor Relations scott@anebulo.com Rex Merchant CFO rex@anebulo.com
Anebulo Pharmaceuticals — Technical Presentation (July 2022) on 6ix